why choose us

300×250 Ad Slot

Research Article: Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China

Date Published: 2023-08-16

Abstract:
Objective The ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP came at high costs, and its economy is not clear. Therefore, this study aimed to evaluate the cost-effectiveness of SEP from the perspective of the Chinese healthcare system. Design A partition survival model was built to simulate the outcomes. The clinical data came from the ASTRUM-005 trial, and only direct medical costs were included in the model. The utility values referred to the published literature. Scenario analyses 1 and 2 explored outcomes in the presence of a patient assistance plan (PAP) and different simulation periods, respectively. Scenario analysis 3 compared the cost-effectiveness of atezolizumab plus chemotherapy (AEP) with SEP by network meta-analysis. Sensitivity analyses were conducted to assess the robustness of the results. Outcome measures Total costs, incremental costs, life years, quality-adjusted life years (QALYs), incremental QALYs and incremental cost-effectiveness ratio (ICER). Results Compared with chemotherapy, SEP achieved an additional 0.34 QALYs at incremental costs of US$41?682.63, with an ICER of US$122?378.86/QALY. When PAP was available, ICER was US$58?316.46/QALY. In the simulation time of 5 years and 20 years, the ICER was US$132?637.97/QALY and US$118?054.59/QALY, respectively. When compared with AEP, SEP not only reduced the costs by US$47 244.87 but also gained 0.07 QALYs more. Sensitivity analyses showed that the price of serplulimab and the utility value of the progression-free survival stage were the main influencing parameters, and the results were stable. Conclusions Compared with chemotherapy, SEP was not cost-effective from the perspective of the Chinese healthcare system. However, SEP was absolutely dominant in comparison with AEP.

Introduction:
Lung cancer is one of the most common malignant tumours. Since 2000, the incidence and mortality of lung cancer in China have been increasing year by year. 1 2 According to the statistics of Global Cancer 2020, the number of new lung cancer cases and deaths in the world was about 2.2?million and 1.8?million, respectively, and the number of lung cancer cases and deaths in China accounted for 37.0% and 39.8% of the world’s total, ranking first in cancer incidence and mortality. 3 Small cell lung cancer (SCLC) is the…

Read more

300×250 Ad Slot